World class leadership.

It started with a question, “What if we could detect cancer before tumors start?”

Dr. Chris Yu

Co-Founder / Chief Executive Officer

Dr. Yu has enjoyed a successful career as an innovator in life sciences, engineering and technology.

  • Worked for three U.S. Fortune 500 companies.
  • First or principal Inventor of over 300 patent applications spanning semiconductor, materials and life science.
  • Proven history developing cutting-edge products with long-term profit and sustainability.
  • Received his bachelor and master’s degrees in physics from the University of Missouri Kansus-City Campus, and a doctoral degree in physics from the Pennsylvania State University. His master’s and doctoral dissertations both addressed innovative detection techniques.

Dr. Herbert Yu

Co-founder/Chief Medical Officer

  • Renowned expert in a molecular epidemiologist, with training in medicine, epidemiology, and clinical biochemistry.
  • 20 year career in leading-edge cancer research including, breakthrough work in the areas of carcinogenic factors & molecular epidemiology.
  • Professor & Research Director at University of Hawaii & Adjunct Professor at Yale University.
  • Received his doctor’s degree in medicine from Shanghai First Medical College in 1983. He also received a master of science degree in epidemiology and a PhD in clinical biochemistry from University of Toronto in 1990 and 1996, respectively.

Weidong Dai

China General Manager

  • Served as a general partner at Stirrfir Investment Management Co., Chairman of RTS Management (Shanghai) Co., and Managing director of Hong Kong Pro-Health Technology Co., and Shanghai Pro-Health Medical Devices Co.
  • Was Chief Scientific Officer at Wex International Inc. (a subsidiary of a U.S. listed company) and an adjunct professor at Anhui College of Traditional Chinese Medicine.
  • Has published a number of medical research papers and scientific articles in professional journals and was awarded the Hong Kong Industrial Award for a medical device that he led in research and development.
  • Received his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

Rain Yu Zhang

Chief Financial Officer

  • Served as a general manager-operation at Buckman Laboratories (Asia) Pte. Ltd. (Singapore) and finance director at Buckman Laboratories Shanghai Chemicals Co., Ltd.
  • She is a Chartered Global Management Accountant (CGMA) and Certified Public Accountant.
  • Received bachelor’s degree in accounting from Shanghai University of Finance and Economics and master’s degree in business administration from AnTai College of Economics & Management, Shanghai Jiao Tong University.

Early cancer screening saves lives and dramatically reduces costs.

Results speak.

26

Cancer types detected

880+

Individuals screened out & identified with an early stage of disease

85-90%

Sensitivity & specificity for most cancer types

140,000+

General population screening & clinical research samples

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article
©2019 Anpac Bio-Medical Science Co., Ltd.
;